Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Mirum Pharmaceuticals will host an investor call on September 28, 2026, to disclose topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis D virus (HDV). The announcement contains no clinical efficacy, safety, or financial results, but the forthcoming pivotal-study readout could be a meaningful catalyst for the company.